Personalized melanoma vaccine cuts recurrence or death risk 42%

By Tom Whitfield

A personalized melanoma vaccine reduced the risk of melanoma recurrence or death by 42% when added to standard immunotherapy in a 1,137-patient international phase 3 trial, Melanoma Institute Australia reported. The result moves intismeran autogene into regulatory review, but the treatment remains unavailable while regulators assess the evidence.

What did the phase 3 trial show?

The trial enrolled 1,137 patients at 157 sites worldwide, including Australian hospitals and cancer centres. It tested intismeran autogene with pembrolizumab in people with surgically resected melanoma at high risk of recurrence. Melanoma Institute Australia called it the world's first international phase 3 trial of a personalized cancer vaccine and said it performed better than expected.

The reported benefit came from adding the vaccine to standard immunotherapy, not from administering the vaccine alone. The measured outcome was recurrence or death; the available figures did not include follow-up duration, absolute-risk change, confidence intervals or p values. Without those data, the 42% finding cannot establish a 42-percentage-point survival gain.

How does the personalized mRNA vaccine work?

Unlike traditional vaccines, intismeran autogene is tailored to each patient's tumor. Researchers compare cancer cells with healthy cells to identify distinctive features, then use that information to create an mRNA vaccine. The vaccine trains the immune system to recognize those features and target melanoma cells if the cancer returns.

The regimen has two components. The vaccine teaches the immune system what to look for if melanoma returns, while pembrolizumab attacks the cancer. Recipients therefore receive the vaccine and existing immunotherapy together, rather than the vaccine as a stand-alone treatment.

Who could receive the treatment?

At this stage, the announced indication covers people who have already had melanoma removed through surgery and remain at high risk of recurrence. It is not a vaccine for preventing melanoma in the first place. Nor is it intended to replace sun protection or regular skin checks.

The announcement did not specify additional eligibility criteria, dosing, treatment duration or follow-up, leaving those operational details unresolved before regulatory review.

Why does Australia have a particular stake?

Australia has one of the highest melanoma rates in the world, with one person diagnosed every 30 minutes. It is also the most common cancer in the country among people aged 20–39. According to Melanoma Institute Australia, Australia is leading development of the world-first personalized cancer vaccine.

The institute said the result points to promise for access in coming years, although regulatory review now determines when or whether the treatment becomes available. The 42% finding applies to the trial regimen and cannot predict the outcome for an individual patient.

Could it lead to personalized vaccines for other cancers?

Researchers believe the approach could pave the way for personalized vaccines that target other forms of cancer. They still need to establish whether tumor-specific vaccine construction and immune training work across other diseases. The melanoma trial provides no efficacy data for other cancers, so broader use remains a research goal.

When will the vaccine become available?

The positive phase 3 result sends intismeran autogene into regulatory review, a process the institute said can take several years. Until that review ends, the vaccine remains unavailable. No regulator, submission date or approval timetable was announced.

The next concrete milestone is completion of regulatory review. If regulators approve the vaccine following review, intismeran autogene could become an additional option to reduce recurrence or death for surgically resected melanoma, used with pembrolizumab. Extending the personalized-vaccine approach beyond melanoma will require separate studies.